Federated Hermes Inc. Cuts Stock Position in 4D Molecular Therapeutics, Inc. $FDMT

Federated Hermes Inc. trimmed its position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 4.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,594,832 shares of the company’s stock after selling 72,506 shares during the quarter. Federated Hermes Inc. owned 3.42% of 4D Molecular Therapeutics worth $13,859,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. BVF Inc. IL boosted its stake in shares of 4D Molecular Therapeutics by 1.5% in the second quarter. BVF Inc. IL now owns 4,629,289 shares of the company’s stock valued at $17,175,000 after purchasing an additional 68,000 shares during the period. Millennium Management LLC lifted its holdings in 4D Molecular Therapeutics by 15.0% during the 1st quarter. Millennium Management LLC now owns 1,633,987 shares of the company’s stock worth $5,278,000 after buying an additional 213,264 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in 4D Molecular Therapeutics by 2.3% in the 3rd quarter. Assenagon Asset Management S.A. now owns 663,657 shares of the company’s stock valued at $5,767,000 after buying an additional 14,832 shares during the period. Raymond James Financial Inc. grew its stake in shares of 4D Molecular Therapeutics by 54.7% in the second quarter. Raymond James Financial Inc. now owns 455,470 shares of the company’s stock worth $1,690,000 after acquiring an additional 161,091 shares in the last quarter. Finally, Peapod Lane Capital LLC increased its position in shares of 4D Molecular Therapeutics by 62.6% during the second quarter. Peapod Lane Capital LLC now owns 318,537 shares of the company’s stock worth $1,182,000 after acquiring an additional 122,684 shares during the period. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on FDMT. Royal Bank Of Canada reiterated an “outperform” rating on shares of 4D Molecular Therapeutics in a report on Wednesday, January 7th. Chardan Capital reiterated a “buy” rating and issued a $26.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday, December 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, January 21st. Leerink Partners reissued an “outperform” rating and issued a $17.00 price objective on shares of 4D Molecular Therapeutics in a research report on Friday, October 31st. Finally, Morgan Stanley upgraded shares of 4D Molecular Therapeutics from an “underweight” rating to an “equal weight” rating in a report on Friday, November 7th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $33.25.

4D Molecular Therapeutics Price Performance

Shares of FDMT opened at $8.86 on Friday. 4D Molecular Therapeutics, Inc. has a 1-year low of $2.23 and a 1-year high of $12.34. The stock has a market cap of $506.17 million, a PE ratio of -2.36 and a beta of 2.99. The firm has a fifty day moving average price of $8.97 and a 200 day moving average price of $8.31.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings data on Monday, November 10th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.02) by $0.01. 4D Molecular Therapeutics had a negative return on equity of 47.27% and a negative net margin of 174,314.17%.The company had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.40 million. As a group, equities analysts expect that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current fiscal year.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.